February 4, 2022 12:57 PM EST
R&D

Pfiz­er lands on For­tune’s most ad­mired list, edg­ing out Dis­ney, Google and Star­bucks in an­nu­al rep­u­ta­tion rank­ing

Beth Snyder Bulik

Senior Editor

The Covid-19 vac­cine ha­lo con­tin­ues for Pfiz­er. This week, the Big Phar­ma came in at No. 4 on For­tune’s an­nu­al rank­ing of the most ad­mired …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times